1, Indications A. Perimembranous ventricular septal defect a. Age > 3 years; b. Weight > 10 kg; c. Simple ventricular septal defect with hemodynamic abnormalities, 3 mm < diameter < 14 mm; d. The upper edge of the ventricular septal defect is ≥ 2 mm from the right coronary valve of the aorta and ≥ 2 mm from the tricuspid diaphragm valve, without aortic right coronary valve dehiscence and aortic regurgitation; e. Ultrasound in the short-axis five-chamber heart section of the aorta between 9 e. Ultrasound in the short-axis five-chamber cardiac section of the aorta between points 9 and 12. B. Basal ventricular septal defect ≥ 3 mm. C. Myocardial infarction or post-traumatic ventricular septal perforation. A. Small ventricular septal defect with a diameter of <3 mm and no obvious hemodynamic abnormality, the purpose of blocking treatment is to avoid or reduce infective endocarditis in patients with small ventricular septal defect; B. Intra-crestal ventricular septal defect, close to the aortic valve, often combined with aortic valve prolapse in adult patients, but if the defect is more than 2 mm from the pulmonary valve and the diameter is less than 5 mm, most of them can be successfully C. 3 months after healing of infective endocarditis and no intracavitary bulges; D. ≤2 mm from the right coronary valve of the aorta, no right coronary valve prolapse, no aortic regurgitation, or mild aortic regurgitation; E. ventricular septal defect combined with first-degree atrioventricular block or second-degree type I conduction block; F. combined with arteriovenous catheter failure, and the arteriovenous catheter failure has F. Interventional treatment is indicated. G. Porous ventricular septal defect with bulging aneurysm, where the upper edge of the defect is more than 2 mm from the aortic valve and the outlet is relatively concentrated, and the left ventricular surface of the blocker can completely cover the entire entrance. H. Post-surgical residual fistula. 3. Contraindications A. Infectious endocarditis, intracardiac redundancy, or other infectious lesions; B. Thrombosis at the placement of the blocker, or venous thrombosis in the path of catheter insertion; C. Huge septal defect, poor anatomical position of the defect, and possible imaging of the aortic valve or atrioventricular function after blocker placement; D. Severe pulmonary hypertension with bidirectional shunts, or even right-to-left shunts; E. Combined E. Combined hemorrhagic disease and thrombocytopenia; interventricular diaphragm defect is one of the most commonly treated disorders, but it is more difficult to operate than atrial defect and arteriovenous catheterization, and the cost is $35,000.